Expert interprets FDA guidance on social media

01/9/2012 | Wall Street Journal, The

Drugmakers should be cautious when soliciting patient testimonials because discussions of off-label use could run afoul of recent FDA guidance, says Dale Cooke, vice president and group director of regulatory review at marketing shop Digitas Health. Drugmakers should also be careful with blogging about clinical trials tied to unapproved uses and ensure that conversations about off-label uses are not in a public forum, he said.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY